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Abstract
Background: Cardiac resynchronization therapy (CRT) is an established treatment in advanced heart failure (HF).
However, an important subset does not derive a significant benefit. Despite an established predictive role in HF,
the significance of right ventricular (RV) dysfunction in predicting clinical benefit from CRT remains unclear. We
investigated the role of RV function, assessed by cardiovascular magnetic resonance (CMR), in predicting response
to and major adverse clinical events in HF patients undergoing CRT.
Methods: Sixty consecutive patients were evaluated with CMR prior to CRT implantation in a tertiary cardiac
centre. The primary end-point was a composite of death from any cause or unplanned hospitalization for a major
cardiovascular event. The secondary end-point was response to therapy, defined as improvement in left ventricular
ejection fraction ≥ 5% on echocardiography at one year.
Results: Eighteen patients (30%) met the primary end-point over a median follow-up period of 26 months, and 27
out of 56 patients (48%) were considered responders to CRT. On time-to-event analysis, only atrial fibrillation (HR
2.6, 95% CI 1.02-6.84, p = 0.047) and RV dysfunction, either by a reduced right ventricular ejection fraction-RVEF (HR
0.96, 95% CI 0.94-0.99, p = 0.006) or tricuspid annular plane systolic excursion-TAPSE (HR 0.88, 95% CI, 0.80-0.96, p =
0.006), were significant predictors of adverse events. On logistic regression analysis, preserved RVEF (OR 1.05, 95%
CI 1.01-1.09, p = 0.01) and myocardial scar burden (OR 0.90, 95% CI 0.83-0.96, p = 0.004) were the sole
independent predictors of response to CRT. Patients with marked RV dysfunction (RVEF < 30%) had a particularly
low response rate (18.2%) to CRT.
Conclusions: Right ventricular function is an important predictor of both response to CRT and long-term clinical
outcome. Routine assessment of the right ventricle should be considered in the evaluation of patients for CRT.
Keywords: heart failure, cardiac resynchronization therapy, right ventricular function, cardiovascular magnetic
resonance
Background
Cardiac resynchronisation therapy (CRT) is an estab-
lished therapeutic option for selected patients with
symptomatic heart failure (HF). Amongst its benefits are
reduced mortality, improved exercise tolerance and
quality of life [1,2]. However, a proportion of patients
do not gain any significant benefit, the reasons for
which are unclear. Thus a number of devices are being
implanted with no discernible clinical benefit, which has
important healthcare costs implications, as well as
exposing patients to unnecessary risks. Our current
strategy for assessing benefit with CRT is mainly
focused on assessing symptomatic or functional
response, but it is increasingly clear that this does not
necessarily translate into improved clinical outcomes. It
is therefore important to refine the selection criteria for
device implantation to better identify those who would
benefit-both in terms of response and improved clinical
outcomes.
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Whilst much attention has focused on remodelling of
the left ventricle (LV), the role of the right ventricle
(RV) in the appropriate selection of patients for CRT
remains unclear [3]. Previous studies assessing RV func-
tion have utilised echocardiography and radionuclide
imaging [4-7]. However, accuracy of RV volumes and
function by these techniques may be inaccurate due to
the anatomical location and complex geometric struc-
ture. Cardiovascular magnetic resonance (CMR) offers
superior three dimensional representation of the RV,
leading to a more accurate and reproducible assessment
of RV function [8]. We therefore sought to assess the
impact of RV function on outcomes in HF patients
undergoing CRT implantation using CMR.
Methods
Study population
We studied 60 consecutive patients attending the Royal
Brompton Hospital heart failure pacing clinic between
January 2005 and March 2010 who fulfilled the follow-
ing criteria: 1. New York Heart Association (NYHA)
class III/IV at the time of CRT implantation; 2. QRS
width ≥ 120 ms; 3. LVEF ≤ 35% by echocardiography,
and; 4. CMR study within 3 months before CRT
implantation.
These patients were evaluated for clinical (aetiology of
heart failure, symptom status and medication, heart rate,
blood pressure) and electrocardiographic (rhythm and
QRS width) parameters at the time of device implanta-
tion. As this study involved review of local patient medi-
cal records, individual consent was not required by our
Ethics Committee who approved the study.
Imaging
Cardiovascular magnetic resonance studies were per-
formed in 1.5T Sonata or Avanto scanners (Siemens,
Erlangen, Germany). A short-axis stack from atrio-ven-
tricular level to the apex was acquired using a steady-
state free-precession cine sequence (echo time 1.6 ms,
repetition time 3.2 ms, flip angle 60°, slice thickness 7
mm with a 3 mm gap, acquisition time of 8-12 cardiac
cycles) to quantify left and right ventricular volumes.
Long-axis cines were also acquired to define the valve
plane throughout the cardiac cycle. An inversion recov-
ery gradient echo sequence was used 10 minutes after
gadolinium injection (Magnevist® or Gadovist® , 0.1
mmol/kg) to assess myocardial scar. Inversion times
were set to null the normal myocardium with images
repeated in two stacks of identical short-axis planes but
separate phase-encoding directions to exclude artefact.
Left and right ventricular volumes were calculated
using semi-automated software (CMR tools, Cardiovas-
cular Imaging Solutions, London, UK), as previously
described (Figure 1) [9,10]. The resulting values were
then indexed to body surface area and compared to
reference values from a control population [9,10]. Tri-
cuspid annular plane systolic excursion (TAPSE) was
measured from the 4-chamber view (Figure 2). RV dys-
function was defined as RVEF < 50% or TAPSE < 15
mm; severe RV dysfunction was defined as RVEF < 30%
or TAPSE < 10 mm. Peak RV wall thickness was mea-
sured from the short-axis slices.
Valvular regurgitation was graded as mild (n = 1),
moderate (n = 2) or severe (n = 3) by blinded observers,
based on the echocardiographic and CMR findings.
LVEF was also calculated by echocardiography before
and 1 year after device implantation using the Simpson’s
method from the 2-chamber and 4-chamber views.
Figure 1 Software used for ventricular volumes and mass
measurements. Mid-ventricular short-axis (top) and four-chamber
views (bottom) at end-diastole (left) and end-systole (right).
Coloured areas represent the left and right ventricular cavities and
myocardium. Ventricular volumes are generated from a short-axis
stack after being confined by the mitral and tricuspid valve planes
(red lines).
Figure 2 Four-chamber view in end-diastole (left panel) and
end-systole (right panel). The tricuspid annular plane is marked as
a white line in diastole and as a dashed line in systole. The red
vector represents the tricuspid annular systolic excursion (TAPSE).
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Pulmonary artery systolic pressure was determined by
echocardiography using standard methodology.
Contrast imaging with gadolinium was performed to
assess the aetiology of the heart failure. Assessment of
late gadolinium enhancement (LGE) in the left or right
ventricle was interpreted by blinded observers. When
present, the amount of LGE was quantified in a 16-seg-
ment model based on the “full width at half maximum”
technique by customized analysis software (MRI-MASS,
Medis, Leiden, the Netherlands) [11].
Outcomes
All patients were followed-up in a heart failure clinic
and standard medications were adjusted and optimized
at these appointments. Data was collected from local
hospital records, nation-wide summary case records and
the Office of National Statistics. The primary end-point
was a composite of all-cause mortality or an unplanned
hospitalization for a major cardiovascular event; only
the first event in each patient was included in this analy-
sis [2]. The secondary end-point was echocardiographic
response to CRT, defined as an improvement in LVEF
by more than 5% by echocardiography 12 months after
CRT implantation [12,13].
Statistical analysis
Categorical variables are presented as frequency and
percentage. Continuous variables are presented as mean
± standard deviation (SD) if normally distributed, or as
median plus inter-quartile range (IQR) as appropriate.
Continuous variables were compared with Student’s t-
test or the Mann-Whitney for non-parametric data. Cor-
relation was assessed with Pearson’s or Spearman’s
methods as appropriate.
Time to first event analysis was performed using Cox’s
proportional hazard models. Log-rank test was used to
compare Kaplan-Meier cumulative event curves. Logistic
regression was used to assess response to CRT at 12
months. Multivariate logistic regression analysis using a
forward stepwise approach was performed on para-
meters that were significant on univariate analysis.
A two-tailed value of p-value < 0.05 was considered
significant. All statistical analysis was performed using
SPSS 19.0 (IBM, Chicago, Illinois, USA).
Results
Patients
Patient baseline characteristics are presented in table 1.
The mean age of the study population was 65.3 ± 12.5
years; most of the patients were male (76.7%). Heart fail-
ure was ischaemic in 48.3% of patients, and atrial fibril-
Table 1 Baseline characteristics of the patients
Age, years 65.3 ± 12.5
Male gender 46 (76.7%)
Heart failure, aetiology
Dilated cardiomyopathy 27 (45.0%)
Ischaemic 29 (48.3%)
Valvular 3 (5.0%)
Congenital 1 (1.7%)
Rhythm
Sinus 46 (76.7%)
Atrial fibrillation 13 (21.7%)
Atrial flutter 1 (1.7%)
Medication
Beta-blockers 43 (71.7%)
ACE inhibitors/ARB 58 (96.7%)
Aldosterone antagonists 39 (65.0%)
Loop diuretics 52 (86.7%)
Digoxin 12 (20.0%)
Aspirin 23 (38.3%)
Warfarin 19 (31.7%)
Statin 30 (50.0%)
ECG
QRS width (ms) 156 ± 21
Heart rate
Beats per minute (bpm) 76 ± 15
Blood pressure
Systolic (mmHg) 120 ± 20
Diastolic (mmHg) 72 ± 13
Left ventricle
EDV (mL/m2) 169 ± 62
ESV (mL/m2) 124 ± 55
EF (%) 27 ± 8
Mass (g/m2) 113 ± 30
Right ventricle
EDV (mL/m2) 82 (65-123)
ESV (mL/m2) 38 (27-76)
EF (%) 52 (37-62)
TAPSE (mm) 13.5 ± 5.6
Peak wall thickness (mm) 3.6 ± 0.9
Pulmonary artery pressure (mmHg) 38.7 ± 8.7
Late gadolinium enhancement
Absent 20 (33.3%)
Subendocardial 19 (31.7%)
Subendocardial + mid-wall 6 (10.0%)
Mid-wall 15 (25.0%)
Right ventricle 5 (8.3%)
Data is presented as n (%), mean ± SD, or median (25th - 75th percentile).
NYHA = New York Heart Association; ACE = angiotensin-converting enzyme;
ARB = angiotensin receptor blocker; BNP = B-type natriuretic peptide; EDV =
End-diastolic volume; ESV = End-systolic volume; EF = Ejection fraction; TAPSE
= tricuspid annular plane systolic excursion.
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lation/flutter was found in 23.3% of patients. The mean
heart rate was 76 ± 15 bpm, and the mean QRS interval
was 156 ± 21 ms (LBBB morphology in 95.0%). The
median time between CMR and device implantation was
6 days. Fifty-six out of the 60 CRT (93%) devices were
combined with a defibrillator (CRT-D).
Left ventricle
Both mean left ventricular indexed end-diastolic and
end-systolic volumes were high (169 ± 62 and 124 ± 55
mL/m2, respectively). The indexed left ventricular end-
diastolic volume was increased in 93% of the patients,
while the indexed left ventricular end-systolic volume
was increased in 99% of the patients compared to normal
reference values [9]. The mean LVEF was 27 ± 8%, and
the mean mass index was increased at 113 ± 30 g/m2.
Mitral regurgitation was seen in 90% of the patients,
and was significant in 25% of patients (18% moderate,
7% severe). Aortic regurgitation was seen in 25% of
patients, and was moderate in only one patient.
Right ventricle
Right ventricular indexed volumes and ejection fraction
were non-normally distributed, and hence presented as
median plus inter-quartile ranges. The median end-dia-
stolic and end-systolic volumes were 82 (65-123) mL/m2
and 38 (27-76) mL/m2, respectively. Right ventricular
indexed end-diastolic volume was increased in 38% of
patients, while the indexed end-systolic volume was
increased in 53% of patients [10]. The median RVEF
was 52% (IQR 37-62%), with 53% of patients having a
RVEF ≥ 50%.
The mean TAPSE was 13.5 ± 5.6 mm, with 40% of
patients having values within normal limits when the
standard echocardiographic cut-off value of 15 mm was
considered. The mean peak RV wall thickness was 3.6 ±
0.9 mm.
In the 52 patients (87%) in whom it could be mea-
sured, the mean PASP was 38.7 ± 8.7 mmHg, with 37%
of patients having a PAP > 40 mmHg. Tricuspid regur-
gitation was seen in 57% of the patients, and was signifi-
cant in 14% of patients (12% moderate, 2% severe). No
significant pulmonary regurgitation was identified in any
patient.
There was a moderately strong correlation between
RVEF with TAPSE (r = 0.58, p < 0.01), and a moder-
ate correlation between RVEF and LVEF (r = 0.41, p <
0.01). Severity of mitral regurgitation was associated
with a higher PAP (p = 0.01) and a lower RVEF (p <
0.01). Modest inverse correlations were observed
between RVEF and pulmonary artery pressure (r =
-0.37, p < 0.01), RV wall thickness (r = -0.28, p =
0.03) and severity of tricuspid regurgitation (p = 0.03).
TAPSE was inversely related with RV wall thickness
(r = -0.29, p = 0.03), but not with pulmonary
artery pressure (r = -0.15, p = 0.28) or LVEF (r = 0.09,
p = 0.48).
RVEF was similar in patients with an ischaemic and
non-ischaemic aetiology (46.9 ± 14.8% vs. 49.5 ± 18.9, p
= 0.56), and in patients with AF compared to those in
sinus rhythm (45.4 ± 14.9% vs. 49.2 ± 17.8%, p = 0.48).
Myocardial fibrosis
Left ventricular LGE was present in two-thirds of the
patients: 19 patients (31.7%) had sub-endocardial
enhancement suggesting myocardial infarction, 15
patients (25.0%) had a mid-wall enhancement pattern
indicating fibrosis, and the remaining 6 patients (10.0%)
had a mixed pattern of myocardial infarction and mid-
wall fibrosis. Myocardial infarction was therefore present
in 25 patients (41.7%): the septal wall was affected in 11
patients; the inferolateral wall was involved in 15
patients. The median percentage of scar in the myocar-
dium was 4% (IQR 0-18%).
Right ventricular LGE was present in 5 patients (8.3%).
All these patients had coronary artery disease with infer-
ior myocardial infarctions of the LV extending to the
inferior free wall of the RV.
Follow-up
During a median follow-up of 26.1 months (IQR 16.1-
39.3 months) after CRT implantation, there were 13
unplanned hospitalizations for a cardiovascular cause
(all for heart failure decompensation), and 11 deaths (8
cardiac and 3 non-cardiac deaths). The primary end-
point was reached by 18 patients. Atrial fibrillation and
RV dysfunction emerged as the only predictors of the
primary composite end-point on univariate analysis
(table 2). Patients in atrial fibrillation or flutter had a
HR of 2.6 (95% CI 1.02-6.84, p = 0.047) for the primary
end-point. For each 10% decrease in RVEF, the risk of
the primary end-point increased by 40% (HR 0.96, 95%
CI 0.94-0.99, p = 0.006); for each 1 mm decrease in
TAPSE, the risk of the primary end-point increased by
12% (HR 0.88, 95% CI 0.80-0.96, p = 0.006). Kaplan-
Meier curves for RV function assessed by RVEF or
TAPSE are displayed on Figure 3.
After documenting AF as a predictor of outcomes, we
performed a post-hoc analysis on delivery rate, defined
as the percentage of paced left ventricular beats. Data
was collected from routine pacing clinic visits during
the first year of implantation. Unlike AF, delivery rate
was not associated with the primary end-point (HR 0.97,
95% CI 0.88-1.08, p = 0.56).
Response to therapy
Of the 56 patients (93%) followed-up for over a year,
27 were considered to be responders as they had an
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increase in LVEF > 5% at one year of follow-up. Thus
the response rate using this criterion was 48% (table
3).
Two sets of closely related parameters were associated
with non-response to CRT on univariate analysis: (1)
coronary artery disease, associated with myocardial
infarction and scar burden (myocardial fibrosis plus
infarction relative to LV mass), were predictors of non-
response to therapy; (2) right ventricular dysfunction
(lower RVEF and TAPSE) and hypertrophy (thicker RV
free wall). Myocardial scar burden (OR 0.90, 95% CI
0.83-0.96, p = 0.004) and RVEF (OR 1.05, 95% CI 1.01-
1.09, p = 0.01) were the only variables to remain signifi-
cant on multivariate analysis (table 4).
Table 2 Univariate analysis: Primary end-point (time to death from any cause or an unplanned hospitalization for a
major cardiovascular event).
Events (n = 18) No Events (n = 42) HR 95% CI P value
Age (years) 69.6 ± 11.9 63.3 ± 12.3 1.04 0.99-1.09 0.07
Male gender 14 (78%) 32 (76%) 1.14 0.37-3.46 0.82
CAD 10 (56%) 17 (41%) 1.73 0.68-4.38 0.25
Atrial fibrillation 6 (39%) 8 (17%) 2.63 1.02-6.84 0.047
Heart rate (bpm) 79.2 ± 19.4 74.1 ± 12.5 1.02 0.99-1.05 0.22
SBP (mmHg) 124 ± 22 118 ± 19 1.01 0.99-1.04 0.36
QRS width (ms) 151 ± 25 158 ± 21 0.99 0.96-1.01 0.23
Left ventricle
EDV index (mL/m2) 159 ± 54 173 ± 64 0.99 0.98-1.00 0.09
ESV index (mL/m2) 120 ± 52 126 ± 56 0.99 0.98-1.00 0.19
EF (%) 26.9 ± 9.5 28.9 ± 7.6 1.00 0.94-1.06 0.93
Mass index (g/m2) 106 ± 25 115 ± 32 0.98 0.97-1.00 0.08
Mitral regurgitation 1.3 ± 0.6 1.2 ± 0.8 1.33 0.73-2.44 0.35
LGE 13 (72%) 27 (64%) 1.57 0.50-3.98 0.51
LGE (%) 9.5 (0-20) 3 (0-17) 1.01 0.98-1.05 0.54
Myocardial infarction 9 (50%) 16 (38%) 1.57 0.62-3.95 0.34
Right ventricle
EDV index (mL/m2) 95 (76-138) 77 (60-103) 1.01 1.00-1.02 0.12
ESV index (mL/m2) 52 (35-102) 34 (21-66) 1.01 1.00-1.02 0.06
EF (%) 39 (25-54) 55 (43-66) 0.96 0.94-0.99 0.006
TAPSE (mm) 11.0 ± 4.4 14.5 ± 5.9 0.88 0.80-0.96 0.006
Wall thickness (mm) 3.9 ± 1.0 3.5 ± 0.9 1.54 0.93-2.56 0.09
PAP (mmHg) 42.5 ± 8.3 37.5 ± 8.5 1.06 1.00-1.12 0.07
Values are n (%), mean ± SD, or median (25th - 75th percentile). HR = hazard ratio; CI = confidence interval. CAD = Coronary artery disease; SBP = systolic blood
pressure; LGE = late gadolinium enhancement; PAP = Pulmonary artery pressure. Other abbreviations as in table 1.
Figure 3 Kaplan-Meier estimates of the time to the primary end-point for RVEF (left panel) and TAPSE (right panel).
Alpendurada et al. Journal of Cardiovascular Magnetic Resonance 2011, 13:68
http://www.jcmr-online.com/content/13/1/68
Page 5 of 10
Response to CRT was noted to be lower as RV func-
tion deteriorated (Figure 4). Poor RV function, defined
as a RVEF < 30% or a TAPSE < 10 mm, was associated
with a particularly low response to CRT (response rates
of 18.2% and 26.7%, respectively).
Discussion
This study shows that RV dysfunction is associated with
non-response and adverse outcomes in patients on CRT.
Despite meeting the standard criteria for CRT implanta-
tion, there was a heterogeneous distribution of RV func-
tion in our study population. Since LVEF was narrowly
distributed by accepted indications for CRT, the wide
RVEF distribution observed may indeed explain why RV
function was an independent discriminator in this popu-
lation with advanced HF. A lower RVEF was associated
with a lower LVEF, more significant mitral regurgitation,
and a higher PAP. This suggests that the RV
dysfunction may derive from two fundamental mechan-
isms, the importance of which may vary from patient to
patient: 1) an impairment of global biventricular intrin-
sic contractility; 2) pulmonary hypertension secondary
to elevated LV filling pressures and mitral regurgitation.
Adverse RV function may reflect more extensive and
severe cardiac disease, to which improving myocardial
synchrony has little impact. Of note, the response rate
of the subgroup of patients with RVEF < 0.3 was less
than 20%. Thus, patients with poor RV function were
unlikely to benefit from CRT. This may have implica-
tions in stratifying patients for device therapy.
Previous work
Few studies have investigated RV function and dyssyn-
chrony. Previous work has shown that anything up to
20-40% of RV systolic pressure and volume load may
originate from contraction from the LV [14].
Table 3 Univariate analysis: Response to cardiac resynchronization therapy (improvement of LVEF ≥ 5% at one year).
Response Response (n = 27) No Response (n = 29) OR 95% CI P value
Age 64.0 ± 12.2 65.8 ± 12.2 0.99 0.95-1.03 0.58
Male gender 18 (67%) 25 (86%) 0.32 0.09-1.20 0.09
CAD 7 (26%) 19 (66%) 0.18 0.06-0.58 0.004
Atrial fibrillation 4 (15%) 7 (24%) 0.55 0.14-2.13 0.38
Heart rate (bpm) 76 ± 15 76 ± 16 1.00 0.97-1.04 0.89
SBP (mmHg) 120 ± 20 119 ± 19 1.00 0.98-1.03 0.76
QRS width (ms) 161 ± 21 150 ± 22 1.02 1.00-1.05 0.07
Left ventricle
EDV index (mL/m2) 156 ± 46 177 ± 71 0.99 0.98-1.00 0.19
ESV index (mL/m2) 111 ± 40 133 ± 63 0.99 0.98-1.00 0.13
EF (%) 30.5 ± 8.5 26.5 ± 7.2 1.07 0.99-1.16 0.07
Mass index (g/m2) 108 ± 26 118 ± 34 0.99 0.97-1.01 0.23
Mitral regurgitation 1.1 ± 0.6 1.3 ± 0.8 0.58 0.27-1.27 0.17
LGE 13 (48%) 24 (83%) 0.19 0.06-0.66 0.009
LGE (%) 0 (0-7) 13 (3-22) 0.91 0.85-0.97 0.005
Myocardial infarction 6 (22%) 18 (62%) 0.18 0.05-0.57 0.004
Right ventricle
EDV index (mL/m2) 77 (67-104) 83 (61-139) 0.99 0.98-1.01 0.28
ESV index (mL/m2) 36 (23-54) 40 (31-96) 0.99 0.98-1.00 0.10
EF (%) 56 (45-63) 44 (28-61) 1.04 1.01-1.08 0.03
TAPSE (mm) 15.3 ± 5.8 11.8 ± 4.2 1.15 1.03-1.29 0.02
Wall thickness (mm) 3.3 ± 0.7 4.0 ± 1.0 0.42 0.21-0.84 0.02
PAP (mmHg) 36.9 ± 8.5 40.5 ± 9.0 0.95 0.89-1.02 0.16
Values are n (%), mean ± SD, or median (25th-75th percentile). OR = odds ratio; CI = confidence interval. Other abbreviations as in tables 1 and 2.
Table 4 Multivariate analysis: Response to cardiac resynchronization therapy (improvement of LVEF ≥ 5% at one
year).
Response Response (n = 27) No Response (n = 29) OR 95% CI P value
LGE (%) 0 (0-7) 13 (3-22) 0.90 0.83-0.96 0.004
RVEF (%) 56 (45-63) 44 (28-61) 1.05 1.01-1.09 0.01
Values are median (25th-75th percentile). OR = odds ratio; CI = confidence interval; LGE = late gadolinium enhancement; RVEF = right ventricular ejection
fraction
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Conversely, left bundle branch block (LBBB) may inter-
fere with ventricular activation and induce mechanical
dyssynchrony. Hence LBBB not only affects LV function
but may impair RV function as well.
RV functional indices have been previously evaluated
in CRT populations. Initial work by Field et al assessed
RV function on adverse outcomes in a population of 77
patients undergoing CRT. This study showed that RV
dysfunction measured by the Doppler-derived Tei index
was a predictor of the composite end-point of death,
transplantation and the implantation of left ventricular
assist devices [4]. More recent work focused on RV
function and response to CRT. In a study of 44 patients
undergoing CRT, echocardiographic indices of RV func-
tion (TAPSE and RV fractional area change) were signif-
icantly worse in non-responders versus responders to
CRT [5]. The value of TAPSE in predicting reverse
remodelling was further validated in the CARE-HF
population [6]. A further radionuclide imaging study in
44 patients undergoing CRT showed that those with a
low baseline RVEF were less likely to improve in NYHA
class, and tended to improve less in functional capacity
and LVEF [7].
The results of our study are in line with the above
publications. However, we used CMR as the gold-stan-
dard technique for assessment of the RV, and RVEF as
the reference marker of RV performance. Along with
myocardial infarction, RVEF was an independent predic-
tor of response to CRT. Among an array of established
prognostic markers in HF, RVEF and TAPSE emerged
as the strongest predictors of events. Our findings corre-
lated response with outcomes over a clinically relevant
timeframe, thus supporting the potential of RV function
as a predictor of short-term response as well as longer-
term outcome following CRT.
Tricuspid annular plane systolic excursion
Although available to all imaging modalities, and despite
its validated prognostic value amongst cardiac and pul-
monary conditions, RVEF estimation can be challenging
as the right ventricle is a complex structure which can-
not be modelled with simple geometric assumptions.
Therefore, there is some interest in finding simpler ways
for assessing RV performance. Of these, tricuspid annu-
lar plane systolic excursion (TAPSE) is the most
described alternative to RVEF in the literature [15]. This
marker of RV longitudinal function is reproducible and
easy to obtain, and has shown to be a predictor of
adverse outcomes in heart failure, irrespective of NYHA
status and LV function [16,17]. In this study, TAPSE
not only identified which patients would respond to
CRT, but also the patients more likely to have major
adverse events. Thus, TAPSE may be used by CMR as
an alternative to RVEF for assessing RV function pre
CRT when the latter cannot be estimated.
Pulmonary hypertension
Increased pulmonary artery pressures have shown to be
associated with non-response to CRT [5]. As ejection
fraction is influenced by the afterload, it is expected for
increasing pulmonary pressures to be associated with
decreasing RVEF. A significant negative correlation was
indeed observed between PAP and RVEF in our study.
However, this correlation was modest and not as strong
as other parameters such as LVEF, suggesting that fac-
tors other than pulmonary hypertension play a role in
RV function. There was a trend for non-response to
CRT and adverse outcomes in patients with increased
pulmonary pressures, but statistical significance was not
reached, probably explained by the smaller study popu-
lation compared to other studies [18]. On the other
Figure 4 Frequency of primary events and response to CRT for different ranges of RVEF and TAPSE.
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hand, markers of RV function were significantly asso-
ciated with response and adverse events. This suggests
that RV function is more important than pulmonary
pressure alone for both mechanical response and long-
term prognosis in patients on CRT.
Myocardial fibrosis
Late gadolinium enhancement CMR detects myocardial
infarction accurately, with superior histological correlation
compared to nuclear techniques [19]. This has become an
active area of research in the CRT setting, with several
subsequent studies documenting the value of scar burden,
location and transmurality of myocardial infarctions as a
predictor of response to CRT [20-24]. Consistent with this
work, our study showed myocardial infarction and scar
burden (as determined by percentage of LGE mass) to
portend an adverse response to CRT. Although the
amount of septal and lateral scar was associated with non-
response to therapy (OR 0.99, 95% CI 0.98-1.00, p = 0.02;
and OR 0.98, 95% CI 0.97-1.00, p = 0.02, respectively),
scar location did not remain significant after including the
total amount of scar in a multivariate model.
The lack of response observed with the above para-
meters did not translate into poorer outcomes. It is pos-
sible that this study was underpowered to detect more
adverse events, as larger studies have shown ischaemic
heart disease and location of myocardial infarction to
portend a worse prognosis in CRT [25-27].
Atrial fibrillation
Atrial fibrillation was the other predictor of outcomes
besides RV dysfunction. This mirrors findings of long
term studies of patients on CRT [28]. It is recognised
that AF with a high ventricular rate may impair the
delivery of biventricular pacing, and consequently
undermine the clinical benefit of CRT [29]. Despite the
paucity of data from randomized control trials in AF
populations, recent guidelines support the use of CRT
in AF patients, although restricted to a slightly wider
QRS duration > 130 ms [30]. A recent European registry
suggests that around 20% of patients undergoing CRT
are actually in permanent AF, which is in keeping with
our findings [31]. Of note, all but one AF patient in this
study had QRS > 130 ms. Rate control was satisfactory
in our AF cohort, the ventricular delivery rate was high
(median 97%, IQR 91-99%), and none of the patients
underwent AV nodal ablation. Unlike RV dysfunction,
AF was not associated with a lower response rate, sug-
gesting that the impact of AF on adverse outcomes was
not altered by device implantation.
Response
In addition to the hard clinical endpoints, we assessed the
role of RV function on response to CRT. Response is a
contentious topic, with various proposed definitions but
no consensus amongst different criteria. The response
rate varies widely, depending on the study population
and the response criteria used. In a recent paper compar-
ing 15 response criteria from the most cited papers, the
response rate ranged from 32% to 91%. The same study
showed that the agreement between different criteria was
poor in 75% of the time, especially between clinical and
echocardiographic criteria [32]. For our study, we used
LVEF to assess response because it is an objective para-
meter and is also one of the selection criteria for CRT. In
keeping with previous work, response for this study was
an improvement in LVEF ≥ 5% at 12 months [12,13]. The
response rate observed was relatively low (48%), but still
in accordance with the available literature [32]. Using
this criterion, RV dysfunction predicted a failure of
response to CRT in terms of LV remodelling, thus sup-
porting previous echocardiographic and radionuclide stu-
dies [5-7]. It is possible that significant RV dysfunction
marks extensive and irreversible adverse remodelling,
preventing reverse remodelling and functional recovery
after CRT implantation. Improvement in LVEF ≥ 5% was
significantly associated with event-free survival in this
cohort of patients (likelihood ratio 4.7, p = 0.01).
Mechanical remodelling thus appears to be a good surro-
gate marker of response to therapy, in line with a recently
published analysis of the MADIT-CRT trial, where it was
demonstrated that echocardiographic improvement in
LV volumes and ejection fraction was associated with
improved outcomes [33].
Limitations
This was a retrospective study with a relatively small
number of patients and events limiting multivariate ana-
lysis on outcomes. Nonetheless, both RVEF and TAPSE
emerged as the most significant prognostic markers,
suggesting that RV function as assessed by CMR has a
powerful role in advanced HF undergoing CRT.
This was a single centre study in a tertiary referral
hospital, but it allowed for consistent CMR scanning
protocols, and consistent patient selection for CRT and
close follow-up of all patients. To ensure a representa-
tive cohort, consecutive patients were identified.
The CRT devices implanted during this time period
were non-MRI compatible and hence necessitated an
alternative imaging modality for consequent follow-up.
The development of CMR-compatible CRT devices
could overcome this current limitation and may provide
new insights on the response of both left and right ven-
tricle to CRT.
Conclusions
Right ventricular function appears an important predic-
tor of response and major adverse events following CRT
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implantation. As current selection criteria only include
patients with poor LV function, it is reasonable to
assume that RV function will act as an important discri-
minative prognostic marker in patients undergoing
CRT. Furthermore, poor RV function appears to identify
a subgroup of patients with extensive ventricular remo-
delling unlikely to change their natural history. There-
fore, CRT may be of no benefit in this subgroup of
patients. The presence and amount of myocardial fibro-
sis, by contrast, was a predictor of response but did not
predict outcomes.
The results of this study suggest that assessment of
RV function can provide valuable information pre CRT
implantation. Further work in larger cohorts is required
to ascertain the precise role of RV evaluation in the
selection of patients for CRT as well as the mechanisms
for this dysfunction.
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